homepage-top-section

Vertex has licensed the technology for use in up to three drug targets, as part of the agreement. The Hypercon microparticle platform enables hyperconcentration of drugs and biologics,

The transaction will expand Neurocrine’s portfolio in endocrinology and rare diseases via the addition of Soleno’s lead product, Vykat XR (diazoxide choline), for Prader-Willi syndrome (PWS). Vykat XR

The approval in the European Union (EU) is for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma whose tumours are PD-L1 positive, with a combined

Under the agreement, Biocytogen’s fully human antibody discovery platform will be combined with Sihuan Pharmaceutical’s capabilities in drug development, manufacturing, and commercialisation. The collaboration will focus on advanced

The partnership focuses on progressing Cellinfinity BIO’s programmes CIB-301 and CIB-350. uBriGene’s LVV Turbo platform will provide good manufacturing practice (GMP) lentiviral vector manufacturing, production, process development, and

It is indicated as an adjunct to exercise and diet for improving glycaemic control. The FDA’s decision is based on data from the ONWARDS Phase IIIa clinical programme,

The partnerships aim to apply AI within scientifically validated modelling workflows and define scalable, next-generation approaches throughout the drug development life cycle. The programmes will use Simulations Plus

Daiichi Sankyo will utilise Tempus’ foundation models such as PRISM2, which integrates pathology images and clinical data to generate diagnostic and predictive insights. The partnership will combine Daiichi

Under the agreement, Quotient will receive $20m upfront and could also earn up to $2.2bn through regulatory, development, and commercial milestone payments. Quotient’s somatic genomics approach analyses naturally